









Markets
/
Stocks
/
nasdaq-argx
/

argenx SE

ARGX

697.050USD

0.0000.00%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

43.14BMarket Cap

33.07P/E TTM



argenx SE

697.050

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of argenx SE

Currency: USD Updated: 2026-03-25

Key Insights

argenx SE's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 107 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1017.29.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

argenx SE's Score

Industry at a Glance

Industry Ranking

107 / 391

Overall Ranking

224 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

argenx SE Highlights

StrengthsRisks

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 4.15B.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 238.52% year-on-year.

Overvalued

The company’s latest PE is 33.07, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 32.28M shares, increasing 0.23% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 114.00 shares of this stock.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

1017.290

Target Price

+49.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of argenx SE is 4.51, ranking 387 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.29B, representing a year-over-year increase of 74.12%, while its net profit experienced a year-over-year increase of 31.16%.

Score

Industry at a Glance

Previous score

4.51

Change



Financials

5.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

2.21

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

6.91

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

argenx SE's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of argenx SE is 5.45, ranking 375 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 33.07, which is 45.96% below the recent high of 48.27 and 2828.29% above the recent low of -902.21.

Score

Industry at a Glance

Previous score

5.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 107/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of argenx SE is 8.62, ranking 95 out of 391 in the Biotechnology & Medical Research industry. The average price target is 925.00, with a high of 1124.00 and a low of 715.00.

Score

Industry at a Glance

Previous score

8.62

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

1017.290

Target Price

+49.20%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

argenx SE

ARGX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

Kymera Therapeutics Inc

KYMR

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of argenx SE is 6.99, ranking 140 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 778.22 and the support level at 638.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.721

Sell

RSI(14)

37.959

Neutral

STOCH(KDJ)(9,3,3)

42.188

Buy

ATR(14)

19.327

Low Volatility

CCI(14)

-33.689

Neutral

Williams %R

59.283

Sell

TRIX(12,20)

-0.725

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

680.966

Buy

MA10

690.823

Buy

MA20

717.946

Sell

MA50

785.357

Sell

MA100

826.261

Sell

MA200

751.544

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of argenx SE is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 58.19%, representing a quarter-over-quarter decrease of 0.61%. The largest institutional shareholder is PRFDX, holding a total of 2.67M shares, representing 4.37% of shares outstanding, with 41.97% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.48M

+5.08%

T. Rowe Price Associates, Inc.

Star Investors

2.81M

-31.29%

Janus Henderson Investors

2.58M

+0.38%

Capital World Investors

1.96M

+0.43%

Artisan Partners Limited Partnership

2.19M

-6.95%

Avoro Capital Advisors LLC

990.00K

-15.74%

T. Rowe Price International Ltd

828.77K

-6.66%

Wellington Management Company, LLP

729.99K

+80.10%

RTW Investments L.P.

673.50K

ClearBridge Investments, LLC

756.86K

-2.07%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of argenx SE is 9.10, ranking 3 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.